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Background: Genetic testing for BRCA1 and BRCA2 has led to the accurate identification of individuals at higher risk
of cancer and the development of new therapies. Approximately 10-20% of the genetic testing for BRCA1 and
BRCA2 leads to the identification of variants of uncertain significance (VUS), with higher proportions in Asians. We
investigated the functional significance of 7 BRCA1 and 25 BRCA2 variants in a multi-ethnic Asian cohort using a
case-control approach.
Methods: The MassARRAY genotyping was conducted in 1,394 Chinese, 406 Malay and 310 Indian breast cancer
cases and 1,071 Chinese, 167 Malay and 255 Indian healthy controls. The association of individual variant with
breast cancer risk was analyzed using logistic regression model adjusted for ethnicity, age and family history.
Results: Our study confirmed BRCA2 p.Ile3412Val is presented in >2% of unaffected women and is likely benign,
and BRCA2 p.Ala1996Thr which is predicted to be likely pathogenic by in-silico models is presented in 2% of healthy
Indian women suggesting that it may not be associated with breast cancer risk. Single-variant analysis suggests that
BRCA1 p.Arg762Ser may be associated with breast cancer risk (OR = 7.4; 95% CI, 0.9–62.3; p = 0.06).
Conclusions: Our study shows that BRCA2 p.Ile3412Val and p.Ala1996Thr are likely benign and highlights the need
for population-specific studies to determine the likely functional significance of population-specific variants. Our
study also suggests that BRCA1 p.Arg762Ser may be associated with increased risk of breast cancer but other
methods or larger studies are required to determine a more precise estimate of breast cancer risk.
Keywords: BRCA1, BRCA2, Variant of uncertain significance, Malaysia, AsiaBackground
Germline mutations in BRCA1 (MIM 113705) and
BRCA2 (MIM 600185) are associated with increased risk
of breast and ovarian cancer. The discovery of germline
mutations has led to the accurate identification of indi-
viduals who are at risk of cancer and the development of
new therapies for the disease. In many countries, indi-
viduals with a priori risk of 10–20% of having inherited* Correspondence: soohwang.teo@cancerresearch.my
†Equal contributors
1Cancer Research Malaysia, 1 Jalan SS12/1A, 47500 Subang Jaya, Selangor,
Malaysia
4Breast Cancer Research Unit, University Malaya Cancer Research Institute,
Faculty of Medicine, University Malaya Medical Centre, University Malaya,
50603 Kuala Lumpur, Malaysia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zea germline mutation in BRCA1 and BRCA2 are offered
genetic counselling and testing [1] and on average, 17–20%
of the genetic testing for BRCA1 and BRCA2 detect patho-
genic mutations [2, 3]. However, approximately 10–20% of
the tests lead to the identification of variants of uncertain
significance (VUS) which comprise missense variants, in-
tronic variants, synonymous variants and in-frame inser-
tions or deletions [4, 5], for which the clinical relevance
remains equivocal.
The frequency of VUS varies by ancestry around the
world with lower frequency in populations that are well
studied such as the Caucasian population in North
America and Europe, and high frequency in populations
such as Asian, African and Middle Eastern where there
has been little study and limited availability of geneticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Lai et al. BMC Cancer  (2017) 17:149 Page 2 of 8counselling and testing [6]. Over time, VUS are system-
atically reclassified as additional information or evidence
is supported [7, 8]. According to a study reported by
Myriad Genetics in United States based on 20 years of
experience, the frequency of VUS in BRCA1 and BRCA2
declined from 12.8 to 2.1% [6]. Notably, the frequency of
VUS remains the highest in Asians with 7% of the tests
reported as VUS. Although the pathogenicity of VUS
has been studied using different approaches such as
multifactorial likelihood model, population frequency,
functional or mRNA splicing assay, the majority of these
are focused on VUS in the Caucasian population [9–11].
In Asia, studies have reported novel variants but the
clinical significance of these variants has not been fur-
ther investigated [12–15].
In this study, we analyzed the frequency of 7 BRCA1
and 25 BRCA2 variants in an Asian cohort of 2,110
breast cancer patients and 1,493 healthy women, in
which the pathogenicity of variants is evaluated using a
case-control approach.Methods
Study description
The recruitment of breast cancer patients into the
Malaysian Breast Cancer Genetic Study (MyBrCa)
started in January 2003 at University Malaya Medical
Centre, and in September 2012 at Subang Jaya Medical
Centre in Kuala Lumpur, Malaysia. All were histopath-
ology proven breast carcinoma. Blood, demographic and
family history data were collected from breast cancer pa-
tients who consented to participate in this study.
From January 2003 to March 2014, 2,323 breast cancer
patients were recruited into the study. A total of 467 in-
dividuals were selected for germline analysis on the basis
of age of onset and family history of breast and/or ovar-
ian cancer, in which 402 of the cases have been previ-
ously described [15–18] and 65 additional cases were
tested using the same selection criteria. Detection of
germline mutations was conducted using direct DNA se-
quencing and multiplex ligation-dependent probe ampli-
fication (MLPA) on the BRCA1 and BRCA2 genes.
Of the 2,323 breast cancer patients, cases were excluded
if they were of mixed parentage or ethnicities other than
Chinese, Malay or Indian (n = 87), or had insufficient or
low quality genomic DNA (n = 126), leaving a cohort of
2,110 individuals (1,394 Chinese, 406 Malay and 310
Indian) for genotyping. Controls were selected from 1,530
women with no personal history of breast cancer attend-
ing an opportunistic mammography screening program
from October 2011 to April 2013 [19]. A total of 37 con-
trols who were of mixed parentage or ethnicities other
than Chinese, Malay or Indian (n = 37) were excluded.
The remaining 1,493 individuals consisting of 1,071Chinese, 167 Malay and 255 Indian with sufficient
genomic DNA were genotyped.
Selection and genotyping of variants
The germline analysis identified 69 missense and intronic
variants of BRCA1 and BRCA2 from 109 individuals. All
variants identified from the germline analysis, regardless
of their predicted clinical importance, were selected for
genotyping to evaluate their frequency using a case-
control approach. The variants were annotated according
to Human Genome Variation Society (HGVS) recommen-
dations based on transcript sequence of BRCA1
(NM_007294.3) and BRCA2 (NM_000059.3). Two vari-
ants (BRCA1 p.Asp345Tyr and BRCA2 c.632-10dupT)
failed in assay design due to repetitive nucleotides located
at neighboring sequence of each variant. Of the remaining
variants, 23 BRCA1 and 44 BRCA2 variants were included
in the genotyping assay (Additional file 1: Table S1a and
S1b).
Genotyping was conducted using SEQUENOM iPlex
multiplex single-base extension assays and analyzed by
MALDI-TOF mass spectrometry (SEQUENOM Inc., San
Diego, USA). Individuals who were previously analyzed
by direct DNA sequencing and MLPA were used as
positive and negative controls for genotyping. The geno-
typing process involved two phases in which the assay of
Phase 1 included 27 variants (9 BRCA1 and 18 BRCA2)
and tested on 879 breast cancer cases recruited from
January 2003 to July 2010. In Phase 2, the remaining 40
variants (14 BRCA1 and 26 BRCA2) were added to the
assay and this was tested on a non-overlapping cohort of
1,231 breast cancer cases and 1,493 healthy controls
recruited from July 2010 to March 2014 (Additional file
1: Table S1a and S1b). Where possible, all cases and con-
trols participating in the research study were included in
the genotyping assay. The subsequent variant analyses
were performed according to the number of genotyped
cases and controls for each variant. Variants with geno-
typing call rate of <95% were excluded. Approximately
5% of the randomly selected samples were duplicated in
the experiment and samples that were failed to be geno-
typed in >20% of the assays were excluded.
In-silico prediction
The effect of missense variants on protein function was
predicted using AGVGD (http://agvgd.hci.utah.edu/),
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and
SIFT (http://sift.jcvi.org/). AGVGD is an evolutionary se-
quence conservation model in which the algorithm eval-
uates the physiochemical properties of amino acid and
multiple sequence alignments in a substituted protein
sequence [20]. PolyPhen-2 uses sequence-based and
structure-based predictive features to evaluate the dam-
aging effects of missense variants [21]. SIFT predicts the
Table 1 Characteristics of Malaysian breast cancer cases and
healthy controls
Characteristics Breast cancer cases Healthy controls p-value
N = 2,110 N = 1,493
N % N %
Ethnicity <0.001
Chinese 1,394 66.1 1,071 71.7
Malay 406 19.2 167 11.2
Indian 310 14.7 255 17.1
Agea (years)
Average age 49.5 50.3 0.009
≤ 30 76 3.6 0 0
31–40 337 16.0 72 4.8
41–50 751 35.6 781 52.3
51–60 623 29.5 501 33.6
≥ 61 323 15.3 139 9.3
Family historyb 0.001
Yes 506 24.0 288 19.3
No 1,598 75.7 1,205 80.7




Triple negative 242 11.5
No data 199 9.4
a Age of diagnosis for breast cancer cases or age of consent for
healthy controls
b Family history of breast or ovarian cancer in first or second degree relatives
Lai et al. BMC Cancer  (2017) 17:149 Page 3 of 8effects of all possible substitutions at each position in
the protein sequence by using sequence homology [22].
Statistical analyses
The information on ethnicity, age of diagnosis or con-
sent, and family history of breast or ovarian cancer in
first and second degree relatives were obtained from the
questionnaires. The association between breast cancer
risk and these baseline characteristics was investigated
using t-test for age and Chi-Square for ethnicity and
family history. We assessed the relationship between
each variant and the risk of breast cancer using logistic
regression model adjusted for ethnicity, age and family
history. All statistical analyses for single-variant associ-
ation testing were performed using Statistical Package
and Service Solutions (SPSS) version 16.0. The R package
‘rmeta’ (version 2.16; https://cran.r-project.org/web/pack-
ages/rmeta/index.html) was used to generate the forest
plot of single-variant association in the Additional file 2.
Results
We determined the spectrum of BRCA1 and BRCA2
deleterious mutations and variants in 467 breast cancer
patients by full sequence analysis and large genomic
rearrangement analysis. Of these, 69 (14.8%) had germline
deleterious mutations and 125 (26.8%) had variants in
BRCA1 and BRCA2 genes. In total, 24 BRCA1 and 45
BRCA2 missense and intronic variants were identified
from 109 individuals. Of these 69 variants, 67 variants that
could be designed for the MassARRAY platform were
included in a multiplex genotyping assay (Additional file
1: Table S1a and S1b).
The genotyping assay was tested on 2,110 breast cancer
cases and 1,493 healthy controls (Table 1). Majority of the
individuals recruited for this study were Chinese (66.1% in
cases and 71.7% in controls), followed by Malay (19.2% in
cases and 11.2% in controls) and Indian (14.7% in cases
and 17.1% in controls). The average age of breast cancer
cases (49.5 years) was slightly younger than healthy
controls (50.3 years). Notably, there was no difference in
age for cases and controls for Chinese and Indian women,
but healthy women were on average 2 years older than the
cases for Malay women (Additional file 1: Table S2).
Ethnicity, age and family history of breast or ovarian
cancer were significantly associated with breast cancer risk
and hence were included as covariates in single-variant
association testing.
Genotyping of 2 BRCA1 (c.-19-3A >G and c.-19-10 T >
C) and 2 BRCA2 (p.His523Arg and p.Arg2502His) vari-
ants resulted in genotyping call rates of <95%, and these
variants were therefore excluded from the analysis. We
also excluded 19 cases and 29 controls from analysis
because these samples were failed to be genotyped in
>20% of the assays. As a result, 2,091 breast cancerpatients and 1,464 healthy controls were analyzed using a
case-control approach. The genotyping cohort also in-
cluded 120 individuals who were previously analyzed by
germline analysis. Of these, genotyping was concordant
with sequencing in 119 of 120 individuals (99.2%). Ap-
proximately 5% of randomly selected samples (88 cases
and 67 controls) were duplicated in the genotyping assay
and the concordance rate among the duplicated samples
was 98.7% (153/155).
We identified BRCA2 p.Ile3412Val with variant fre-
quency >2% in unaffected women and an additional four
variants (BRCA2 p.Cys315Ser, p.Ile1929Val, p.Arg2108Cys
and p.Lys2729Asn) with variant frequency >1% in un-
affected women (Table 3). All of these are unlikely to be
associated with increased risk of breast cancer.
Of the 63 variants that were included in the analysis,
thirty-one variants (14 BRCA1 and 17 BRCA2) could
not be evaluated as carriers were present only in either
breast cancer cases or healthy controls. Only 32 variants
(7 BRCA1 and 25 BRCA2) were present in both cases
and controls and these were analyzed for association
with breast cancer risk (Tables 2 and 3).
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gression, BRCA1 p.Arg762Ser was associated with breast
cancer risk with a marginal significance (OR = 7.4; 95% CI,
0.9–62.3; p = 0.06) (Additional file 2: Figure S1). This vari-
ant was found in 5 out of 858 Chinese breast cancer pa-
tients (0.6%) and 1 out of 1,054 Chinese controls (0.1%)
(Additional file 1: Table S3), and was marginally associated
with breast cancer risk in Chinese women (OR = 6.7; 95%
CI, 0.8–57.6; p = 0.08) (Additional file 2: Figure S2). The
average age of diagnosis was 39 years old, 25% of
women had estrogen receptor (ER) negative breast
cancer but none reported any family history of breast
or ovarian cancer. The BRCA1 p.Pro346Ser was asso-
ciated with breast cancer risk in Chinese women [5 out of
859 Chinese breast cancer patients (0.6%) and 2 out of
1,055 Chinese controls (0.2%), OR = 3.3; 95% CI, 0.6–17.3;
p = 0.15] (Additional file 1: Table S3a and Additional file 2:
Figure S2), but the results were not statistically significant.
The average age of diagnosis was 62 years old, 20% of
women had ER negative breast cancer but none reported
any family history of breast or ovarian cancer. None of the
BRCA2 variants were significantly associated with breast
cancer risk either in the overall cohort, or when stratified
by ethnicity (Additional file 2: Figure S1 and S2).
The probability that missense variants were deleterious
to protein function was assessed by three in-silico models,
namely AGVGD, PolyPhen-2 and SIFT. Of the 29
missense variants that have been analyzed, three (BRCA2
p.Ala1996Thr, p.Gly2901Asp and p.Tyr3035Cys) were
predicted to be likely pathogenic (Tables 2 and 3).
Discussion
In this study, we analyzed the frequency of 7 BRCA1
and 25 BRCA2 variants from exonic and intronic regions
identified previously in Malaysian breast cancer patients
by germline analysis. The genotyping of variants was
conducted using a high-throughput mass spectrometry
platform [18].
The variant frequency suggested that one of the 63 tested
variants has a minor allelic frequency of >2% in unaffected
women and is likely to be benign [6]. Four variants that
had more than 1% of variant frequency in unaffected
women could be potentially benign. Of these variants, three
(BRCA2 p.Ile1929Val, p.Lys2729Asn and p.Ile3412Val) have
been classified as Class 1 (not pathogenic) and one (BRCA2
p.Arg2108Cys) has been classified as Class 2 (likely not
pathogenic) in either Breast Cancer Information Core Data-
base (http://research.nhgri.nih.gov/bic/) or DatabaseARUP
Laboratories BRCA Mutation Database (http://arup.uta-
h.edu/database/BRCA/) using different approaches [20, 23].
Moreover, BRCA2 p.Ile3412Val was also reported by EN-
IGMA (http://enigmaconsortium.org/) as benign variant to
occur in non-founder African control reference group at an
allele frequency ≥1%. Although BRCA2 p.Lys2729Asn waspredicted to have damaging effect by PolyPhen-2 and SIFT,
the prediction models may have limitation to predict the
actual consequences of missense mutation accurately [24]
therefore the population frequency supersedes the predic-
tion models [8]. These findings are in accordance with the
results of our study which concluded that these variants are
benign variants or polymorphisms.
The clinical significance of BRCA2 p.Cys315Ser and
p.Arg2108Cys is currently listed as uncertain, but our
study suggests that these variants are likely to be benign.
This is consistent with a study in Chinese women from
Shanghai in which BRCA2 p.Cys315Ser was detected in
1.4% of cases and 0.9% of controls, compared with 0.9%
of cases and 1.2% of controls in our study [12]. Notably,
BRCA2 p.Arg2108Cys was evaluated as pathogenic in
spontaneous homologous recombination [25], but our
study suggests that this variant is unlikely to be associ-
ated with high risk of breast cancer.
It was estimated that the rare variant had a relative risk of
above 2 and above 4 might confer moderate and high risk
of breast cancer, respectively [26, 27]. Our study suggests
that one BRCA1 variant may be associated with increased
risk of breast cancer. The BRCA1 p.Arg762Ser may be as-
sociated with breast cancer risk with a marginal significance
(p = 0.06). This variant was previously found in Chinese
and Malay women and the clinical significance is currently
unknown [12, 28, 29]. Although the in-silico analyses pre-
dicted the amino acid substitution of this variant is unlikely
to have damaging effect to protein function, our study sug-
gests that this warrants further analyses in Asian women.
Notably, three BRCA2 variants (p.Ala1996Thr, p.Gly2901Asp
and p.Tyr3035Cys) which are predicted to be pathogenic
by in-silico prediction models were found in cases and in
healthy controls. The clinical significance of BRCA2
p.Ala1996Thr is currently listed as uncertain and the sub-
stitution of valine at the same codon (p.Ala1996Val) in a
Western European woman is also uncertain [7]. BRCA2
p.Gly2901Asp was suggested as neutral in mouse embry-
onic stem cell-based functional assay [30], and predicted
to be uncertain in protein likelihood ratios [31] and
homology-directed repair activity [32]. Although BRCA2
p.Tyr3035Cys was predicted to be likely deleterious in
protein likelihood ratios [31], this variant did not show
any significant association with breast cancer risk in our
study.
There are several limitations to this study. The breast
cancer cases were not age- and ethnicity-matched with
controls in this study, but these variables were adjusted
for all variant analyses. Another limitation is that major-
ity of the variants selected for this study are rare in our
population. These rare variants were detected in very
low frequency, thus decrease the statistical power in a
case-control study. Analyses in larger groups are neces-
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Our data suggests that BRCA2 p.Ile3412Val is likely to
be benign and BRCA1 p.Arg762Ser is likely to be associ-
ated with breast cancer risk. This study could contribute
the evidence to support the characterization of variants
with uncertain significance in BRCA1 and BRCA2.
Additional files
Additional file 1: Table S1a. BRCA1 variants included in genotyping
assay design. A total of 23 BRCA1 variants were included in the genotyping
assay. Of these, two variants were excluded due to genotyping call rate
<95%. Table S1b. BRCA2 variants included in genotyping assay design. A
total of 44 BRCA2 variants were included in the genotyping assay. Of these,
two variants were excluded due to genotyping call rate <95%. Table S2.
Characteristics of Malaysian breast cancer cases and healthy controls in
ethnicity subgroups: (a) Chinese, (b) Malay and (c) Indian. There was no
difference in age for cases and controls for Chinese and Indian women, but
healthy women were on average 2 years older than the cases for Malay
women. Table S3a. Frequency of BRCA1 variants detected in ethnicity
subgroups. The table describes the frequency of BRCA1 variants detected in
Chinese, Malay and Indian women. Table S3b. Frequency of BRCA2 variants
detected in ethnicity subgroups. The table describes the frequency of
BRCA2 variants detected in Chinese, Malay and Indian women. (DOCX 195
kb)
Additional file 2: Figure S1. Association of BRCA1 and BRCA2 variants
with breast cancer risk in all breast cancer cases and healthy controls. The
forest plot illustrates the association of BRCA1 and BRCA2 variants with
breast cancer risk in all breast cancer cases and healthy controls. Figure S2.
Association of variants with breast cancer risk in ethnicity subgroups: (a)
BRCA1 and (b) BRCA2. The forest plot illustrates the association of BRCA1 and
BRCA2 variants with breast cancer risk in certain ethnicity subgroups that
can be analyzed. (DOCX 145 kb)
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